Evidence map›Paper›PMID 32448979›Full record

ArticleArchivum immunologiae et therapiae experimentalis2020

Exopolysaccharide from Lactobacillus rhamnosus KL37 Inhibits T Cell-dependent Immune Response in Mice.

Bernadeta Nowak, Małgorzata Śróttek, Marta Ciszek-Lenda, Anna Skałkowska, Andrzej Gamian, Sabina Górska, Janusz Marcinkiewicz

Open access · hybridAbstract read
In one paragraph

Article in Archivum immunologiae et therapiae experimentalis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Characterization and Heterologous Expression of UDP-Glucose 4-Epimerase From aFrontiers in bioengineering and biotechnology · 2021
    Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Bernadeta NowakDepartment of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121, Kraków, Poland.ORCID http://orcid.org/0000-0003-3513-8803
Małgorzata ŚróttekDepartment of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121, Kraków, Poland.
Marta Ciszek-LendaDepartment of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121, Kraków, Poland.ORCID http://orcid.org/0000-0002-9952-9929
Anna SkałkowskaDepartment of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121, Kraków, Poland.ORCID http://orcid.org/0000-0003-3252-2367
Andrzej GamianLaboratory of Medical Microbiology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.ORCID http://orcid.org/0000-0002-2206-6591
Sabina GórskaLaboratory of Microbiome Immunology, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wrocław, Poland.ORCID http://orcid.org/0000-0002-3206-0695
Janusz MarcinkiewiczDepartment of Immunology, Jagiellonian University Medical College, Czysta 18, 31-121, Kraków, Poland. mmmarcin@cyf-kr.edu.pl.ORCID http://orcid.org/0000-0001-7302-6648
Jagiellonian University · PLLudwik Hirszfeld Institute of Immunology and Experimental Therapy · PL

Funding

Ministerstwo Nauki i Szkolnictwa Wyższego N N401042438Uniwersytet Jagielloński Collegium Medicum K/ZDS/000678
6 · The paper itself

Abstract

Exopolysaccharides (EPSs), major components of the bacterial biofilm, display strong strain-specific immunomodulatory properties. Previously, we have shown that crude EPS derived from Lactobacillus rhamnosus KL37 depresses the production of arthritogenic anti-collagen IgG and ameliorates collagen-induced arthritis (CIA) in DBA/1 mice, when lipopolysaccharide (LPS) was used as adjuvant. In this study, we used highly purified EPS from L. rhamnosus KL37 (EPS-37) to verify its anti-inflammatory properties and the ability to suppress T cell-dependent humoral response. We have employed the model of active CIA, in which mice immunized with type II collagen (CII) along with LPS were treated with pure EPS-37. Intravenous administration of purified EPS-37 markedly ameliorated arthritis and reduced CII-specific antibody production. EPS-37 injected subcutaneously reduced the clinical symptoms of CIA but without the reduction of arthritogenic antibodies. In addition, the effect of EPS-37 on T-cell functions was tested ex vivo and in vitro. EPS-37 inhibited the in vitro proliferation of T cells activated both in vivo (CII immunization) and in vitro (antigen/mitogen), and markedly reduced the production of interferon (IFN)-γ. These results together with other reports suggest that anti-inflammatory potential of EPS-37 depends on its ability to inhibit either one or the other or both possible inflammatory signaling pathways. Namely, Th1 → IFN-γ → M1 inflammatory macrophages → arthritis and/or Th1 → IFN-γ → B cells → arthritogenic antibodies → arthritis. We suggest that L. rhamnosus KL37 EPS might be utilized to control T cell-dependent immune responses in various inflammatory diseases. However, the most effective route of EPS-37 administration needs to be tailored for a given disorder.

Indexed as

AnimalsAnti-Inflammatory AgentsArthritisArthritis, ExperimentalAutoantibodiesCell ProliferationCells, CulturedDisease Models, AnimalHumansImmunity, HumoralImmunosuppression TherapyInterferon-gammaLacticaseibacillus rhamnosusLymphocyte ActivationMiceMice, Inbred DBAAnti-Inflammatory AgentsAutoantibodiesInterferon-gammaPolysaccharides, BacterialCollagen-induced arthritisExopolysaccharideImmunomodulationInflammationLactobacillus rhamnosusT cells

Identifiers

PMID32448979
PMCPMC7246254
OpenAlexW3026309750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.